StockNews.com Initiates Coverage on Nabriva Therapeutics (NASDAQ:NBRV)
by Teresa Graham · The Cerbat GemStockNews.com assumed coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV – Free Report) in a research note released on Monday. The firm issued a hold rating on the biotechnology company’s stock.
Nabriva Therapeutics Price Performance
The firm has a market capitalization of $45.46 million, a P/E ratio of -0.07 and a beta of 1.53. Nabriva Therapeutics has a 12-month low of $1.22 and a 12-month high of $8.45. The company has a debt-to-equity ratio of 0.12, a current ratio of 0.85 and a quick ratio of 0.52.
About Nabriva Therapeutics
Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration.
Further Reading
- Five stocks we like better than Nabriva Therapeutics
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge
- Want to Profit on the Downtrend? Downtrends, Explained.
- How the Fed’s Rate Cut Could Supercharge These 3 ETFs
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Microsoft Stock: 3 Reasons It’s Ready to Crush Q4